ReviewFrontiers in pharmacology2023
Research advances in drug therapy of endometriosis.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Exploring New Treatment Strategies for Endometriosis-Narrative Review.International journal of molecular sciences · 2026Review
- Macrophage membrane-biomimetic nanovehicles delivering amygdalin halt pyroptosis propagation and alleviate endometriosis-associated neuropathic pain.Materials today. Bio · 2026Article
- The Microbiota-Endometriosis Axis: An Immune-Endocrine Integration Model and Emerging Therapeutic Targets.International journal of molecular sciences · 2026Review
- The role of tumor necrosis factor alpha in regulating CYFRA 21-1 as a potential biomarker for endometriosis: A cross-sectional study.International journal of reproductive biomedicine · 2026Article
- Three-dimensional patient-derived endometriosis model for drug evaluation.Acta obstetricia et gynecologica Scandinavica · 2026Article
- Exploring the potential of gut microbiota metabolites in the treatment of endometriosis through network pharmacology and Mendelian randomization.Frontiers in microbiology · 2026Article
- Current Insights into Endometriosis: Hormonal Management, Clinical Outcomes, and Opportunities for Progress.Current pharmaceutical design · 2026Review
- Linzagolix - new perspectives in the pharmacotherapeutic management of uterine fibroids and endometriosis.Przeglad menopauzalny = Menopause review · 2025Review
- Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research.Journal of clinical medicine research · 2025Review
- Endometriosis: An Immunologist's Perspective.International journal of molecular sciences · 2025Review
- Endometriosis and autoimmunity.Autoimmunity reviews · 2025Review
- Molecular Basis of Impaired Decidualization in the Eutopic Endometrium of Endometriosis Patients.Cells · 2025Review
- Evaluating quality of life improvements in endometriosis patients following laparoscopic surgery using EHP-30 scale.Scientific reports · 2025Observational
- Effects of warm silver needle acupuncture combined with myofascial trigger point intervention on peripheral neutrophil autophagy and alleviation of chronic pelvic pain in women.American journal of translational research · 2025Article
- Recent Trends in Medical Management of Endometriosis.Journal of obstetrics and gynaecology of India · 2024Article
- Article
- Endometriosis: A Comprehensive Analysis of the Pathophysiology, Treatment, and Nutritional Aspects, and Its Repercussions on the Quality of Life of Patients.Biomedicines · 2024Review
- Effects of bazedoxifene on endometriosis in experimental animal models: A systematic review and meta-analysis.Turkish journal of obstetrics and gynecology · 2024Article
- The Hallmarks of Endometriosis.Geburtshilfe und Frauenheilkunde · 2024Article
- Causal Relationship Between Mood Swing and Gynecological Disorders: A Mendelian Randomization Study.International journal of women's health · 2024Article
Corrections and comments
- Erratum issued
- Erratum issued
Authors and funding
11 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometriosis is one of the most common benign gynecological disorders in reproductive-aged women. The major symptoms are chronic pelvic pain and infertility. Despite its profound impact on women's health and quality of life, its pathogenesis has not been fully elucidated, it cannot be cured and the long-term use of drugs yields severe side effects and hinders fertility. This review aims to present the advances in pathogenesis and the newly reported lead compounds and drugs managing endometriosis. This paper investigated Genetic changes, estrogen-dependent inflammation induction, progesterone resistance, imbalance in proliferation and apoptosis, angiogenesis, lymphangiogenesis and neurogenesis, and tissue remodeling in its pathogenesis; and explored the pharmacological mechanisms, constitutive relationships, and application prospects of each compound in the text. To date, Resveratrol, Bay1316957, and bardoxifene were effective against lesions and pain in controlled animal studies. In clinical trials, Quinagolide showed no statistical difference with the placebo group; the results of phase II clinical trial of the IL-33 antibody have not been announced yet; clinical trial stage III of vilaprisan was suspended due to drug toxicity. Elagolix was approved for the treatment of endometriosis-related pain, but clinical studies of Elagolix for the pretreatment of patients with endometriosis to before In vitro fertilization treatment have not been fulfilled. The results of a clinical study of Linzagolix in patients with moderate to severe endometriosis-related pain have not been disclosed yet. Letrozole improved the fertility of patients with mild endometriosis. For endometriosis patients with infertility, oral GnRH antagonists and aromatase inhibitors are promising drugs, especially Elagolix and Letrozole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.